이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

해초로 강화된 크래커 섭취 후 플로로탄닌과 카로티노이드의 생체이용률 (BIO-ALGA)

2026년 11월 10일 업데이트: María Raquel Mateos Briz, National Research Council, Spain

Himanthalia Elongata로 강화된 크래커 섭취 후 플로로탄닌과 카로티노이드의 생체이용률 평가

The study aims to evaluate the bioavailability of phlorotannins and carotenoids from the seaweed Himanthalia elongata in healthy individuals after the consumption of a cracker fortified with this plant species. The study consists of an acute, blinded, randomized, controlled, crossover trial in which each participant consumes both the fortified cracker and a control cracker without seaweed. This design allows the comparison of the bioavailability of these compounds when incorporated into a bakery-based food matrix.

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

The BIO-ALGA study is a nutritional intervention designed to evaluate the bioavailability in humans of bioactive compounds present in the brown seaweed Himanthalia elongata, specifically phlorotannins and carotenoids. These compounds have attracted growing interest in the fields of nutrition and functional foods due to their potential antioxidant, anti-inflammatory, and metabolic regulatory properties. Marine macroalgae, and particularly Himanthalia elongata, are recognized as a valuable source of these compounds, in addition to providing dietary fiber, minerals, and other nutrients that may contribute to the prevention of chronic diseases such as obesity, type 2 diabetes, and cardiovascular disorders. However, for these compounds to exert physiological effects in the human body, they must be absorbed during digestion and reach the systemic circulation. Therefore, studying their bioavailability under real consumption conditions in humans is essential.

To address this objective, the study is designed as an acute, randomized, controlled, crossover, and blinded nutritional intervention conducted in healthy adults. Each participant will consume four functional cracker (approx. 20 g) on separate days: one enriched with Himanthalia elongata and another control cracker with identical formulation but without seaweed. The two interventions will be separated by a washout period of at least fifteen days to avoid carryover effects. The expected sample size is at least ten participants, ideally twelve, with balanced representation of men and women. Eligible participants will be healthy adults aged between 18 and 45 years with a body mass index between 18 and 30 kg/m². Exclusion criteria include, digestive diseases, allergies to the ingredients used in the study, current medication or supplement use, hormonal treatments, recent antibiotic consumption, or pregnancy.

The test product consists of four functional cracker weighing approximately 20 g and containing 1 g of freeze-dried Himanthalia elongata powder. This amount ensures the presence of the target bioactive compounds while remaining within safe dietary limits for iodine intake. The formulation includes rice flour, cornstarch, wheat flour, sesame, baking powder, egg and water. A little olive oil was used to enhance the absorption of carotenoids, such as fucoxanthin. Mannitol is used as a sweetener to provide sweetness without substantially increasing caloric content. The placebo bar has the same composition but does not contain seaweed, allowing direct comparison of the absorption of bioactive compounds delivered through the food matrix.

During the seven days prior to each intervention and throughout the study period, participants will be instructed to avoid the consumption of seaweed products. Additionally, they will complete a three-day dietary record before each intervention. On the intervention day, volunteers will attend the Human Nutrition Unit of the Institute of Food Science, Technology and Nutrition (ICTAN-CSIC) after an overnight fast of at least ten hours. A venous cannula will be inserted to allow repeated blood sampling, after which participants will consume the assigned cracker and remain at the research facility for the entire study day under the supervision of the research team. Throughout the day they will receive a standardized polyphenol-free diet to minimize interference with the analytical detection of metabolites derived from the seaweed.

Blood samples will be collected before intake and at multiple postprandial time points (0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 19, and 24 hours) in order to evaluate the plasma kinetics of the absorbed compounds and their metabolites. Approximately 9 mL of blood will be collected at each time point, resulting in a total volume of 99 mL per intervention. Plasma will be separated by centrifugation and stored at -80 °C until analysis. In parallel, urine samples will be collected at defined intervals (-2 to 0 h, 0-3 h, 3-6 h, 6-9 h, and 9-24 h) to assess the urinary excretion of metabolites derived from the bioactive compounds present in the seaweed.

The collected biological samples will be analyzed using high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry with electrospray ionization (HPLC-ESI-QTOF). Targeted metabolomic approaches will be applied to identify and quantify metabolites derived from phlorotannins and carotenoids present in Himanthalia elongata. Based on plasma concentration profiles and urinary excretion patterns, nutritional kinetic parameters such as maximum concentration (Cmax), time to reach maximum concentration (Tmax), and the area under the concentration-time curve (AUC) will be calculated, as well as the proportion of excreted metabolites relative to the ingested dose. This analytical strategy will allow the characterization of the real bioavailability of these compounds under physiological conditions and the identification of potential biomarkers of seaweed consumption.

The study poses minimal risk to participants, mainly limited to mild and transient discomfort associated with blood sampling. The ingredients used in the functional crackers have been carefully selected to ensure food safety and to maintain micronutrient intake, including iodine, within recommended limits. Although the study does not have a direct therapeutic objective, its results are expected to expand current knowledge about the metabolism and bioavailability of seaweed-derived bioactive compounds in humans and to provide scientific evidence supporting the development of functional foods incorporating marine algae with potential health benefits.

연구 유형

중재적

등록 (실제)

10

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Madrid
      • Madrid, Madrid, 스페인, 28040
        • Institute of Food Science, Technology and Nutrition, Spanish National Research Council (ICTAN-CSIC)

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Body mass index: 18-30 Kg/m2

Exclusion Criteria:

  • Following a vegetarian diet
  • Being pregnant
  • Suffering from digestive diseases (such as irritable bowel syndrome, gastrointestinal ulcers, etc.)
  • Having a history of hypersensitivity or allergies to components of the study foods
  • Following any medication regimen
  • Currently taking or having recently taken antibiotics
  • Having donated blood within the three months prior to the study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Seaweed cracker

Rice flour, wheat flour, cornstarch, Himanthalia elongata (0.94 g), salt, sesame, mannitol, baking powder, olive oil.

Four crackers (20 g) fortified with seaweed Himanthalia elongata

위약 비교기: Control cracker

Rice flour, wheat flour, cornstarch, salt, sesame, mannitol, baking powder, olive oil

Four crackers (20 g) without seaweed in its composition

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Targeted metabolic analysis of phlorotannins in blood/urine samples
기간: 2 moths

Targeted metabolomic analysis of phlorotannins in plasma and urine samples will be conducted using HPLC-QTOF-MS. Quantification of the concentration (μM) will be carried out employing authentic commercial standards, ensuring accurate and reliable measurement of target compounds.

2 moths

2차 결과 측정

결과 측정
측정값 설명
기간
Targeted metabolic analysis of carotenoids in blood/urine samples.
기간: 2 months

Targeted metabolomic analysis of carotenoids in plasma and urine samples will be conducted using HPLC-QTOF-MS. Quantification of the concentration (μM) will be carried out employing authentic commercial standards, ensuring accurate and reliable measurement of target compounds.

2 months
Maximum concentration in blood of metabolites
기간: 2 month

Calculation of the maximum concentration before cracker intake

2 month
Area under the curve (AUC) of metabolites in blood samples
기간: 2 moths

Metabolite concentrations will be measured at different time points in order to calculate the area under the concentration-time curve.

2 moths
Time to maximum concentration (Tmax)
기간: 2 month

The time required to reach the maximum concentration of the metabolites (Tmax).

2 month
Urinary excretion percentage of metabolites
기간: 2 months

Urinary excretion percentage of metabolites

2 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 1일

기본 완료 (실제)

2026년 3월 16일

연구 완료 (실제)

2026년 6월 1일

연구 등록 날짜

최초 제출

2026년 3월 5일

QC 기준을 충족하는 최초 제출

2026년 3월 30일

처음 게시됨 (실제)

2026년 4월 2일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 3월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • BIO-ALGA
  • COOPB24080 (기타 보조금/기금 번호: NRC Spain Scientific Cooperation for Development Programme i-COOP 2024)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

IPD 계획 설명

Individual participant data will be available in open data repositories and may be accessed once the study results are published.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .